|
Originally published In Press as doi:10.1074/jbc.M209341200 on October 18, 2002
J. Biol. Chem., Vol. 277, Issue 52, 50355-50364, December 27, 2002
In Vitro Transport on Cis and Trans Sides of the
Golgi Involves Two Distinct Types of Coatomer and
ADP-ribosylation Factor-independent Transport
Intermediates*
Ashok K.
Pullikuth and
Peggy J.
Weidman§
From the Department of Biochemistry and Molecular Biology, St.
Louis University School of Medicine, St. Louis, Missouri 63104
Received for publication, September 12, 2002, and in revised form, October 17, 2002
 |
ABSTRACT |
The cisternal maturation model proposes that
secretory proteins transit the Golgi in cisternae that mature by the
continuous retrograde transport of Golgi enzymes in vesicles. We have
tested the hypothesis that de novo generation of transport
intermediates containing medial, trans, and trans Golgi network
(TGN) enzymes is reconstituted in vitro. Our
analysis shows that the majority of transport is mediated by a steady
state of transport intermediate production and consumption by Golgi
cisternae, with only a minor contribution of pre-existing transport
intermediates. Transport in the medial and trans regions of the stack
involved intermediates containing Golgi enzymes, apparently moving in a
retrograde direction. In contrast, transport between the trans Golgi
and TGN was exclusively mediated by intermediates containing secretory
protein, as expected for anterograde transport. These intermediates may
be physiologically relevant, because only these two specific types of
intermediates can be detected in cell homogenates. By analogy to
the coatomer (COPI)-independent transport of Golgi enzymes to
the endoplasmic reticulum, the steady-state production of intra-Golgi
transport intermediates was not impaired by inhibition of COPI vesicle
formation. These data suggest a model for COPI-independent intra-Golgi
transport by cisternal maturation with a shift in mechanism to
anterograde transport at the trans Golgi and TGN boundary.
 |
INTRODUCTION |
The Golgi complex is a major crossroads for membrane trafficking
in eucaryotic cells. Consisting of stacked cisternae with anastomosing
membrane networks at the entry and exit faces, the Golgi accepts the
entire secretory output of the
ER,1 removing non-secretory
components for recycling while modifying carbohydrates on secretory
cargo as it passes through the stack. Upon exiting the stack at the
trans Golgi network, a final sorting occurs and the various secretory
components are delivered to the appropriate cellular organelles.
Although these functions of the Golgi are well known, the mechanism by
which secretory cargo moves through the stack has remained elusive. It
is generally agreed that small vesicular carriers, particularly
COPI-coated vesicles, play an essential role in this process, but the
nature of their participation is a subject of intense debate
(1-4).
In vivo studies have definitively demonstrated that COPI
vesicles play an essential role in the recycling of non-secretory components from the Golgi to the ER (5, 6). It has been proposed that a
subpopulation of COPI vesicles also transport secretory protein in
anterograde direction through the Golgi stack (7, 8). Consistent with
this hypothesis, immunoelectron microscopy has revealed a population of
Golgi-associated COPI vesicles that contain secretory protein but lack
detectable recycling components or resident Golgi enzymes (9, 10).
Engineered protein aggregates that are too large to enter COPI vesicles
appear to transit the stack in anterograde-directed megavesicles (11). This hypothesis has been challenged, however, by similar studies that
show an apparent enrichment of Golgi enzymes but not secretory cargo in
peri-Golgi COPI vesicles (12). In addition, large aggregates of
procollagen were observed to transit through the Golgi without apparently leaving the cisternae (13). This mode of transport appears
to apply to small cargo proteins as well. A simultaneous pulse of a
small secretory protein and procollagen entered the Golgi together and
remained together as they transited the stack (14). These in
vivo observations, along with evidence that COPI vesicles
generated in vitro selectively concentrate Golgi-resident enzymes (15), favor a model for intra-Golgi transport by cisternal maturation (reviewed in Refs. 1 and 2). In this model, secretory cargo
is transported forward in cisternae that sequentially mature through
the systematic retrograde transport of Golgi enzymes from cisterna to
cisterna. Although in theory anterograde vesicular transport and
transport by cisternal maturation should be distinguishable by direct
testing, a clear resolution to the dilemma has not been attained.
The transport processes occurring within the compact Golgi stacks of
living cells are not resolvable by the in vivo imaging techniques used so successfully in the analysis of transport to and
from the Golgi (16-18). Consequently, most of what is known about
intra-Golgi transport has been gleaned from the analysis of this
process as reconstituted in vitro. The archetypal in
vitro system reconstitutes transport between mutant Golgi
(mut-Golgi) lacking the medial Golgi enzyme
N-acetylglucosaminyl transferase I (GlcNAc TI) and
glycosylation-competent wild type Golgi (wt-Golgi) (19). Transport is
detected when the secretory protein, vesicular stomatitis virus
glycoprotein (VSV G-protein) originating in the mut-Golgi, becomes
glycosylated by GlcNAc TI originating from wt-Golgi. This in
vitro reconstitution system has been a powerful tool for the
identification of protein components involved in transport, including
COPI and its regulator ARF (20, 21). Nevertheless, even though COPI
vesicles form during an in vitro transport incubation
(22-24), it has been impossible to unambiguously demonstrate that COPI
vesicles are required for intra-Golgi transport in vitro
(25-28).
Various explanations have been proposed to account for this unexpected
discrepancy. The coupling hypothesis proposes that COPI vesicles are
obligatory transport intermediates when formed. However, when COPI
vesicle formation is prevented, uncoupling leads to a non-physiological
fusion between cisternae (25). A few studies have also suggested that
the in vitro system reconstitutes the fusion between
pre-existing transport intermediates that contain GlcNAc T1 and
mut-Golgi cisternae containing VSV G-protein (29, 30). These
intermediates could be bona fide transport intermediates that were formed in vivo, or they could be fusogenic
fragments of cisternae that were formed by disruption of the cells.
Generalizing from these observations, it has been proposed that
transport at all levels of the Golgi stack might occur by retrograde
vesicular transport of Golgi enzymes, rather than anterograde transport of cargo. A final possibility is suggested by the finding that the
retrograde transport of Golgi enzymes to the ER in vivo
occurs by a completely COPI-independent process (31, 32). It is thus possible that the transport of Golgi enzymes in vitro could
involve carriers formed by a similar COPI-independent mechanism.
In the current study, we have measured the extent to which each of
these potential mechanisms contributes to Golgi transport reconstituted
in vitro using minimal perturbation of the system from its
original formulation. The analysis was extended to in vitro
transport at different levels of the Golgi stack to determine whether
the mechanisms are conserved throughout the Golgi. Our data demonstrate
that the majority of in vitro Golgi transport arises, not
from pre-formed transport intermediates, but from a steady state of
transport intermediate production and consumption that is
COPI-independent. In addition, transport on the cis and trans sides of
the Golgi involves two distinct types of intermediates that differ in
their cargo and destination. The same two specific types of carriers
were the only functional transport intermediates detected in broken
cells, suggesting that they may be physiologically relevant
intermediates in intra-Golgi transport.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Radiolabeled nucleotide sugars were purchased from
PerkinElmer Life Sciences (Boston, MA). Palmitoyl coenzyme A and
unlabeled nucleotide sugars were obtained from Roche Biochemicals. All
other chemicals were purchased from either Sigma or VWR Scientific
Products. Monoclonal antibody to COPI (CM1A10) was generous gift of Dr. J. Ostermann. Monoclonal antibodies against ARF (1D9) and -COP (M3A5) were purchased from Affinity Bioreagents.
Cytosol Preparations--
CHO (33) and bovine brain (34)
cytosols were prepared as previously described. ARF-depleted cytosol
was prepared by anion exchange chromatography according to Happe
et al. (27). Briefly, cytosolic protein in TD buffer
(10 mM Tris, pH 7.4, 1 mM dithiothreitol) supplemented with 25 mM KCl and 10 µM EDTA
was loaded onto a Fast-Flow Q anion exchange matrix (Amersham
Biosciences). After elution of unbound protein, ARF was eluted with 65 mM KCl and 1 mM magnesium chloride (in TD), and
the remaining protein was eluted with 500 mM KCl (in TD).
ARF-depleted cytosol was prepared by combining the unbound and 500 mM KCl eluates and concentrating to half the original
volume of cytosol. Reconstituted cytosol was prepared by mixing equal
parts of ARF-depleted cytosol and the similarly concentrated ARF
containing fraction. Unfractionated and reconstituted cytosols had
identical capacity to inhibit transport in the presence of the
non-hydrolysable analog of GTP, GTP S, indicating that ARF function
was reconstituted (27). COPI-depleted cytosol was prepared by
immunodepletion with the COPI monoclonal antibody, CM1A10 (26). Cytosol
was incubated twice with either CM1A10 protein G beads to produce
COPI-depleted cytosol or with c-Myc monoclonal antibody (9E10)
protein G beads to produce mock-depleted cytosol. Depleted cytosols
contained less than 2% of the normal content of ARF or COPI, as
determined by Western blotting with the anti-ARF antibody 1D9 or the
anti- -COP antibody M3A5. All cytosols were free of
transport-competent vesicular contaminants.
Cell-free Transport Assays--
Cell-free assays that measure
transport between the cis and medial Golgi (medial assay (19 and 35)),
medial and trans Golgi (trans assay (27)), and trans Golgi and TGN (TGN
assay (27 and 36)) were as previously described (27). Briefly,
transport mixtures contained buffer salts, cytosol, an ATP-regenerating
system, palmitoyl coenzyme A, mut-Golgi, wt-Golgi, and
nucleotide-3H-sugar (19, 27). Each 25-µl assay
contained an amount wt-Golgi (~0.5-0.75 µg) that was just
sufficient to attain optimal transport with 2.5 µl of mut-Golgi
(~1.5 µg). Golgi-enriched membranes were isolated by sucrose
density flotation from freshly prepared cell homogenates (19). wt-Golgi
isolated from CHO Pro-5 cells were paired with mut-Golgi having defects
in either medial, trans, or TGN-localized N-linked
carbohydrate modifications. The mut-Golgi were prepared from
VSV-infected CHO Lec 1 (GlcNAc TI-deficient (37)), Lec 8 (UDP-galactose
transporter-deficient (37, 38)), and Lec 2 (CMP-sialic acid
transporter-deficient (37, 39)). Transport was measured as the
incorporation of 3H-GlcNAc, 3H-galactose, or
3H-sialic acid into VSV G-protein carbohydrates after a
60-, 90-, or 150-min transport incubation for the medial, trans, or TGN assays, respectively (27).
Two-stage Transport Assays--
Functional vesicular transport
intermediates in the medial, trans, and TGN transport assays were
detected using a two-stage transport assay. In stage I, free transport
intermediates were allowed to form by preincubating either
wt-Golgi or mut-Golgi in a 25-µl transport mixture without the
complementary partner. After 0-60 min of preincubation at 37 °C,
12.5 µl of the mixture was removed and centrifuged for 3 min at
16,000 × g at room temperature. Transport was measured
in stage II of the reaction by mixing either 12.5 µl of the
supernatant or 12.5 µl of the unfractionated stage I reaction with
12.5 µl of a transport mixture containing the complementary membrane
partner (mut- or wt-Golgi). In some experiments, the membrane pellet
from the stage I reaction was resuspended in 12.5 µl of transport
mixture containing 0.2 M sucrose and then subjected to a
stage II transport incubation. Functional intermediates in the medial,
trans, and TGN assays were detected using the transport mixtures and
mut-Golgi specific for each assay, as described above (19, 27). A
background value from a transport incubation without cytosol was
subtracted from the value obtained for each sample.
The cumulative release of intermediates during preincubation was
measured using a variation of this two-stage assay where the membrane
pellet of the stage I reaction was subjected to repeated cycles of
preincubation and re-isolation. After each preincubation step, the
membranes were centrifuged for 90 s at 16,000 × g
at room temperature. The supernatant was added directly to a stage II
transport mixture. The pellet was either gently re-suspended by
pipetting up and down, or simply overlaid with a transport reaction
mixture containing 0.2 M sucrose and incubated again.
Fractionation of Membranes by Velocity
Sedimentation--
Sucrose solutions (% w/w) were prepared in 10 mM Hepes-KOH, pH 7.4, 150 mM KCl, and 2.5 mM magnesium acetate. Equal volumes of 10-37.5% sucrose
in 2.5% increments were used to prepare linear sucrose gradients. Cell
homogenates or Golgi-enriched membranes were layered on top of the
gradient and centrifuged at 4 °C in either an SW41 rotor (40,000 rpm, 274,355 × g) for 35 min or in an SW50.1 rotor
(50,000 rpm, 300,440 × g) for 17 min. 10-13 fractions of equal volume were collected from the top of each tube. Each fraction
was diluted in two steps with an equal volume of 10 mM Tris, pH 7.4 (4 °C), and the membranes were collected by
ultracentrifugation in a TLA100.2 rotor at 100,000 rpm (435,680 × g) for 20-30 min at 4 °C. Membrane pellets were soaked
in 1 M sucrose, diluted to 0.25 M sucrose with
10 mM Tris, pH 7.4 (4 °C), and then gently resuspended.
The concentrated membranes were either assayed immediately or
flash-frozen in liquid nitrogen and stored at 80 °C for later analysis.
Glycosyl Transferase and Nucleotide Sugar Uptake
Assays--
Previously described methods were used to measure
galactosyl transferase and sialyl transferase (40) activities.
Each 50-µl reaction contained 50 mM Tris, pH 7.4, 1 mM ATP, 0.5% Triton X-100, and 5-15 µl of membranes.
The galactosyl transferase reaction mixture also contained 20 mM manganese chloride, 0.1 mM unlabeled UDP-galactose, 10 µCi/ml UDP-3H-galactose, and 14 mg/ml ovalbumin as substrate. The sialyl transferase reaction mixture
contained 0.5 mM unlabeled CMP-SA, 20 µCi/ml CMP-3H-SA, and 12.8 mg/ml asialofetuin as substrate.
Reactions were incubated at 37 °C for 1 h and then precipitated
with 1 ml 5% trichloroacetic acid at 4 °C. trichloroacetic
acid precipitates were collected, washed on glass fiber filters, and
dried for scintillation counting. The background value for a comparable
reaction containing 5.0 mM EDTA (galactosyl transferase) or
incubated on ice (sialyl transferase) was subtracted from each sample.
Membrane uptake of UDP-3H-GlcNAc and CMP-3H-SA
was determined as previously described (41).
 |
RESULTS |
Steady-state Vesicle Production Occurs in Vitro--
Recent
studies demonstrated that vesicular intermediates containing the medial
Golgi enzyme GlcNAc TI can be extracted from Golgi or produced by
mechanical disruption of rat liver Golgi. These intermediates
effectively substituted for wt-Golgi in the cell-free Golgi transport
system referred to here as the medial assay (29, 30). It was thus
proposed that similar intermediates normally present in isolated CHO
Golgi membranes might be responsible for most or all of the transport
reconstituted in the in vitro Golgi transport system. We
directly tested this hypothesis by determining the contribution of
pre-formed intermediates to in vitro transport using the
original formulation of the system with Golgi-enriched membranes from
CHO cells.
A consideration in this analysis was that pre-existing intermediates
might be loosely bound to the Golgi. Because salt extraction of these
intermediates might also remove essential components for de
novo generation of transport intermediates (30, 42), we used an
alternative approach for depleting pre-existing intermediates. Wt-Golgi
were first preincubated in a transport reaction in the absence of
mut-Golgi to allow any pre-existing intermediates to target and fuse
with wt-Golgi cisternae and be consumed. If these intermediates were
the primary source of transport activity in the wt-Golgi preparation,
preincubated wt-Golgi should exhibit a loss of transport capacity when
subjected to a second incubation in the presence of mut-Golgi. In
contrast, if other processes contribute to the activity of the
wt-Golgi, such a preincubation might be expected to have little effect
on the subsequent transport capacity of wt-Golgi. Fig.
1A (triangles)
shows the results obtained when a wt-Golgi were preincubated for
various lengths of time in a transport reaction without mut-Golgi
(stage I) and then incubated again in the presence of mut-Golgi to
measure transport (stage II). Preincubation of the wt-Golgi for up to
40 min had little effect on the subsequent transport activity with
mut-Golgi in stage II, even though the amount of wt-Golgi was limiting
for transport. This suggests that the transport capacity of the
wt-Golgi cannot be solely attributed to pre-existing transport
intermediates.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 1.
Wt-Golgi continuously generate functional
transport intermediates containing GlcNAc TI. A, the
transport activity of free intermediates (squares), residual
cisternae (circles), and unfractionated membranes
(triangles) after the indicated length of stage I
preincubation of wt-Golgi. B, the transport activity of free
intermediates (squares) and unfractionated membranes
(triangles) after a 10-min stage I reaction at the indicated
concentrations of cytosol. Data are the average of two (A)
or five (B) independent experiments and are normalized to
the maximum transport activity (cpm of 3H-sugar
incorporated into VSV G-protein), as determined in a control transport
reaction that was not preincubated (4830 ± 465 cpm and 3396 ± 964 cpm in A and B, respectively).
|
|
The observation that wt-Golgi do not lose their transport activity
after prolonged preincubation might be explained if the wt-Golgi
cisternae were capable of directly fusing with mut-Golgi. Alternatively, a steady state of transport intermediate production and
consumption by wt-Golgi might be maintained during the incubations. To
distinguish between these possibilities, a medium speed centrifugation was used to separate wt-Golgi cisternal membranes from any slowly sedimenting transport intermediates produced in the stage I
preincubation. Each of these fractions was then incubated with
mut-Golgi in stage II to measure transport.
In the absence of a 37 °C preincubation in stage I (Fig.
1A, 0-min time point), about 15-25% of the total transport
capacity of the wt-Golgi (triangle) was recovered in the
supernatant (square). This presumably represents
pre-existing free intermediates that co-purified with the Golgi
membranes. After a 10-min preincubation at 37 °C, the transport
activity of free intermediates increased ~3-fold (Fig. 1A,
squares) and remained constant for up to 40 min. The
transport activity of the residual cisternal membranes (circles) also remained nearly constant for up to 40 min of
wt-Golgi preincubation. This persistence of transport activity in both fractions is indicative of a steady state of free intermediate production and consumption by the wt-Golgi during stage I. Significantly, the activity of the residual cisternal membranes was not
due to liberation of fusogenic membrane fragments during resuspension (29), because similar transport activity was obtained without resuspension (data not shown, but see Figs. 3A and 7).
Furthermore, the steady-state level of transport intermediates was
found to increase with increasing cytosol concentration in stage I
(Fig. 1B). This would not be expected if the intermediates
were generated by mechanical disruption of the Golgi. Thus, the
in vitro system appears to reconstitute both production and
consumption of functional vesicular intermediates containing GlcNAc TI
during a normal in vitro incubation.
Enzyme-containing Intermediates Are Not Universal
Carriers--
The observation that vesicular intermediates containing
GlcNAcT1 are functional in the medial Golgi transport assay suggests the possibility that Golgi enzyme-containing intermediates might mediate transport throughout the stack, as predicted by the cisternal maturation model for intra-Golgi transport (1, 2). We addressed this
possibility by employing two additional cell-free assays that measure
transport either between the medial and trans Golgi (trans assay (27))
or between the trans Golgi and TGN (TGN assay (27, 36)). By analogy to
the medial assay, these cell-free assays employ mut-Golgi that contain
VSV G-protein and are defective in producing N-linked
carbohydrate modifications associated with either the trans Golgi
(galactosylation) or TGN (sialylation). Transport between mut- and
wt-Golgi is thus measured by the incorporation of
3H-galactose (trans assay) or 3H-sialic acid
(TGN assay) into VSV G-protein carbohydrates during the in
vitro incubation. Although the medial, trans, and TGN assays require similar components, the rate of transport, sensitivity to
inhibitors, and optimal transport conditions are assay-specific (27).
This might indicate that there are some mechanistic differences in
transport at different levels of the stack.
Free intermediates were generated in a 10-min preincubation of wt-Golgi
and tested for transport activity in stage II medial, trans, and TGN
assays using the appropriate mut-Golgi and radiolabeled nucleotide
sugars. Unexpectedly, the level of functional intermediates released
from wt-Golgi was highest in the medial assay, lower in the trans
assay, and negligible in the TGN assay (Fig.
2A). The same profile was
observed with different membrane and cytosol preparations,
concentrations of cytosolic protein, and lengths of preincubation (data
not shown), indicating that these variables do not contribute to the
observed differences. The inability to detect Golgi-enzyme-containing
intermediates that are functional in the TGN assay led us to test for
the production of functional intermediates containing secretory cargo.
When the appropriate mut-Golgi were subjected to a 10-min stage I
preincubation and then assayed in stage II with wt-Golgi, no free
intermediates were detected that were functional in the medial and
trans assays (Fig. 2B). In contrast, intermediates derived
from mut-Golgi supported a level of transport in the TGN assay that was
more than half that of unfractionated mutant membranes (Fig.
2B). This suggests that in vitro transport is
mediated by two different types of intermediates on the cis and trans
side of the Golgi stack.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 2.
Distinct vesicular intermediates participate
in transport at different levels of the stack. A and
B, two distinct types of vesicular intermediates participate
in transport on the cis and trans side of the stack. A,
wt-Golgi were preincubated for 10 min in stage I, and the isolated free
intermediates were assayed for transport in stage II with the
assay-specific mut-Golgi for detecting transport of medial, trans, and
TGN-localized Golgi enzymes. B, mut-Golgi for the medial,
trans, and TGN transport assays were preincubated for 10 min in stage
I, and free intermediates were tested for transport activity with
wt-Golgi in stage II. C and D, intermediates
derived from wt- and mut-Golgi selectively fuse with cisternal
membranes. C, free intermediates from a 10-min preincubation
of wt-Golgi were mixed with free intermediates or residual cisternae
from a 10-min stage I preincubation of the appropriate mut-Golgi to
measure transport. D, free intermediates from mut-Golgi were
mixed with wt-Golgi-free intermediates or residual cisternae to measure
transport. The black, hatched, and white
bars indicate transport in the medial, trans, and TGN transport
assays, respectively. Data are the average of a minimum of two
independent experiments and are expressed as the percentage of maximal
transport obtained in a comparable unfractionated transport reaction
(10,146 ± 169, 7,603 ± 1,554, and 2,656 ± 654 cpm in
the medial, trans, and TGN assays, respectively).
|
|
Free Intermediates Fuse with Cisternal Membranes--
If the
transport intermediates derived from both the mut- and wt-Golgi are
physiologically relevant, they should target and fuse with cisternal
membranes and not with other vesicular intermediates. This hypothesis
was tested by preincubating both mut- and wt-Golgi in separate stage I
reactions. For the stage II transport incubation, the free
intermediates from a wt-Golgi or mut-Golgi preincubation were then
mixed with either the free intermediates or residual cisternae from a
mut-Golgi or wt-Golgi stage I preincubation, respectively. In the
medial and trans assays (Fig. 2C, black and crosshatched bars), free intermediates derived from wt-Golgi
fused exclusively with the mutant residual cisternae in the stage II transport reaction. In the TGN assay, there was a corresponding preference for free vesicular intermediates derived from mut-Golgi to
fuse with wild type cisternae (Fig. 2D, white
bar). Under no condition was transport between free intermediates
observed. Intermediates containing either Golgi enzymes or secretory
cargo thus exhibit the fusion specificity expected for physiological
transport intermediates in vectorial transport.
Intermediates Are Continuously Generated during a Transport
Reaction--
The continuous production of free intermediates by Golgi
membranes was demonstrated by measuring the cumulative release of enzyme-containing intermediates after repeated cycles of wt-Golgi preincubation. In the medial assay (Fig.
3A), seven rounds of wt-Golgi
preincubation and re-isolation over a period of 60 min released free
intermediates with a cumulative transport activity (closed
squares) equivalent to the total transport capacity of the
starting membranes (0 min, triangle). The transport activity of the residual cisternae was almost completely exhausted after the
final round (60 min, open diamond). Importantly, similar
results were obtained when the cisternal membranes were not resuspended between rounds (closed circles), indicating that mechanical
disruption of the cisternal membranes during resuspension was not the
cause for continued release of free intermediates.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 3.
Vesicular intermediates are continuously
generated during an in vitro transport reaction.
Preincubated cisternal membranes were re-isolated, resuspended, and
subjected to another round of preincubation at the indicated times. The
free intermediates released at each time point were directly added to a
stage II transport reaction. Cumulative transport was tabulated by
adding the transport activity of free intermediates obtained at a given
time point to the sum of transport for each of the preceding time
points. Data are plotted as the cumulative transport produced by
preincubation of either wt-Golgi (closed squares) or
mut-Golgi (open squares) in the medial (A), trans
(B), and TGN (C) transport assays. Also shown in
A is the total transport capacity of unfractionated wt-Golgi
(closed triangle, 0 min); the cumulative free intermediates
produced by wt-Golgi without resuspension of the cisternal pellet at
each step (closed circles); and the transport capacity of
residual cisternae after 60 cumulative minutes of preincubation with
(open diamond) or without (closed diamond)
resuspension at each step. Transport is given as 3H-sugar
incorporated into VSV G-protein (cpm × 10 3). Data
are representative of a minimum of two independent experiments.
|
|
The cumulative release of free intermediates in the medial assay was
half-maximal at ~10 min of cumulative preincubation of wt-Golgi (Fig.
3A, closed squares), and at ~20 min in the
trans assay (Fig. 3B, closed squares). These
values are identical to the t1/2 for transport in
these assays (27), suggesting that the production of intermediates
containing medial and trans Golgi enzymes is the rate-limiting step for
transport in the medial and trans assays. In contrast, there was almost no detectable cumulative transport activity released from wt-Golgi in
the TGN assay (Fig. 3C, closed squares). Thus,
functional intermediates containing TGN enzymes do not appear to be
produced in the in vitro transport system.
When the cumulative release of functional intermediates from mut-Golgi
was analyzed, virtually all of the transport activity in the TGN assay
could be attributed to the production of free intermediates containing
VSV G-protein (Fig. 3C, open squares). Only a
minor component of such activity was detected in the medial and trans
assays (Fig. 3, A and B, open
squares). Interestingly, the t1/2 for free
intermediate generation in the TGN assay (~17 min) was significantly
faster than the t1/2 for transport (~37 min) (27).
This difference suggests that the production of free intermediates from
mut-Golgi is not the rate-determining step for in vitro
transport to the TGN.
We conclude that there is a uniform mechanism of in vitro
transport on the cis side of the stack involving apparent retrograde transport of Golgi enzymes in vesicular intermediates. At the interface
with the TGN, however, there is a completely unexpected switch to a
mechanism of anterograde transport of cargo in vesicular intermediates.
In both cases, the continuous production of these intermediates is
sufficient to account for the entire transport activity of cisternal
membranes in the in vitro system.
Golgi Enzyme Intermediates Are Abundant in Cells--
The
hypothesis that the transport intermediates generated in
vitro are physiologically relevant would further predict that intermediates with the same specificity for cargo and target
destination are also present at steady state in cells. This prediction
was tested by using velocity sedimentation of wild type cell
homogenates to separate slowly sedimenting intermediates from cisternal
membranes and determining whether the slowly sedimenting membranes
could substitute for wt-Golgi in the three transport assays.
A typical fractionation profile for wild type membranes is shown in
Fig. 4. The cisternal membranes in cell
homogenate sedimented in the bottom half of the gradient, as detected
by the activity of Golgi galactosyl transferase (Fig. 4A,
open circles). Sialyl transferase activity and the uptake of
UDP-3H-GlcNAc and CMP-3H-SA were also maximum
in these fractions (data not shown). Although the slowly sedimenting
membranes in the top half of the gradient (fractions 3-5) contained
negligible glycosyl transferase activities, they exhibited the highest
transport activity with mut-Golgi in the medial (Fig. 4B,
open circles) and trans assays (Fig. 4C, open circles). In contrast, essentially all of the wt-Golgi
activity in the TGN assay was restricted to fractions containing
cisternal membranes (Fig. 4D, open circles).
These data therefore show the specificity predicted by our in
vitro analyses.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 4.
Wild type cells contain free intermediates
that function in medial and trans, but not TGN transport assays.
Cell homogenate (open circles) and Golgi-enriched membranes
(closed circles) from wild type CHO cells were fractionated
by velocity sedimentation. Fractions were assayed for Golgi galactosyl
transferase activity (A) and transport activity with
mut-Golgi in the medial (B), trans (C), and TGN
(D) assays. Here and in Fig. 5, glycosyl transferase
activities are given as percentage of maximum 3H-sugar
incorporated in to substrate. Transport is given as percentage of
maximum 3H-sugar incorporated into VSV G-protein. Data are
representative of a minimum of two independent experiments.
|
|
The abundance of pre-existing functional transport intermediates in
cell homogenates was somewhat surprising, given the small amount of
pre-existing free intermediates that could be detected with isolated
Golgi in the absence of a stage I preincubation (Fig. 1A,
0-min time point). This discrepancy appears to be due to a difference
between the density of the vesicle intermediates and Golgi cisternae.
Velocity sedimentation of Golgi-enriched membranes (isolated from the
same homogenate by equilibrium density centrifugation (19)) revealed
only low levels of pre-existing free intermediates (Fig. 4,
B-D, closed circles, fractions 2-6). The majority of the wt-Golgi activity in all three in vitro
assays reproducibly appeared in the lower half of the gradient with
cisternal membranes. This further supports the conclusion that the
majority of the free intermediates detected in the in vitro
transport system are, in fact, generated de novo. We
conclude that there is a strong correlation between the presence of
functional transport intermediates containing Golgi enzymes in cell
homogenates and the ability of wt-Golgi to generate such functional
transport intermediates in vitro.
Cells Contain Functional Intermediates for TGN Transport--
The
extension of this correlation is that cell homogenates from
VSV-infected mutant cells will contain vesicular transport intermediates that are functional in the TGN assay but not in the
medial or trans assays. Fractionation of homogenates from VSV-infected
CHO Lec 1 and Lec 8 cells, the source for mut-Golgi in the medial and
trans assays, respectively, revealed that essentially all of the
transport activity coincided with the cisternal membrane fractions
(data not shown). This is consistent with the findings of Love et
al. (30) in the medial assay. In contrast, functional VSV
G-protein-containing intermediates were abundant in fractionated homogenates from VSV-infected CHO Lec 2 cells, the source of mut-Golgi for the TGN assay. The majority of the galactosyl transferase activity
was associated with fractions 8-11 (Fig.
5A, open circles), as expected for cisternal membranes. The transport activity of the
fractionated homogenate, however, was greatest in fractions 3-8, with
only a minor peak of activity associated with cisternal membranes (Fig.
5B, open circles). This broad distribution
suggests that the VSV G-protein-containing intermediates may more
resemble the pleiomorphic tubular carriers operating in post-Golgi
trafficking (16) than vesicular carriers. Consistent with this
possibility, the VSV G-protein-containing intermediates were extremely
labile to sedimentation and reisolation, making further
characterization difficult.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
VSV-infected mutant cells contain transport
intermediates that function in the TGN assay. Cell homogenate
(open circles) and Golgi-enriched membranes (closed
circles) from VSV-infected CHO Lec 2 cells (defective in
incorporation of sialic acid) were fractionated by velocity
sedimentation. Fractions were assayed for galactosyl transferase
activity (A) and transport activity with wt-Golgi in the TGN
assay (B).
|
|
For comparison, Golgi-enriched membranes (isolated by equilibrium
density centrifugation from the same cell homogenate) were also
subjected to velocity sedimentation analysis. Only a minor component of
slow sedimenting transport intermediates were detected (Fig.
5B, closed circles). The majority of the
transport activity reproducibly coincided with the peak of galactosyl
transferase activity (Fig. 5A, closed circles).
This suggests that isolation of Golgi cisternal membranes by
equilibrium density flotation either inactivates or removes functional
transport intermediates in the TGN assay. In either case, these data
support the hypothesis that the functional VSV G-protein-containing
intermediates detected in the TGN assay are indeed formed de
novo during the in vitro incubation. Altogether, these
data and those in Figs. 2-4 demonstrate that there is a clear
correlation between the cargo and target specificity of the transport
intermediates formed during an in vitro incubation and the
functional intermediates found in cells after homogenization.
Enzyme Intermediates Formed in Vivo and in Vitro Are
Indistinguishable--
If the transport intermediates formed in
vivo and during an in vitro transport incubation are
related, their size and density should be the same. To test this
hypothesis, a medium speed supernatant of wt CHO cell homogenate,
un-incubated wt-Golgi, and wt-Golgi that had been subjected to a 20-min
stage I preincubation were fractionated by velocity sedimentation, and
the fractions were tested for transport activity in the medial assay
(Fig. 6A). The transport
activity of the un-incubated wt-Golgi was found in the lower half of
the gradient (Fig. 6A, closed circles), as
expected for cisternal membranes. The preincubated wt-Golgi exhibited
this same peak of activity, as well as a new peak of activity near the
top of the gradient (Fig. 6B, closed squares).
This new peak exactly co-migrated with the activity of transport
intermediates in the medium speed supernatant of wt cell homogenate
(Fig. 6A, open circles). By this criterion, the
functional intermediates formed in vivo and in
vitro are indistinguishable.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
Golgi enzyme intermediates produced in
vivo co-sediment with those produced in vitro by a
COPI-independent process. A, a medium speed supernatant
of wt CHO cell homogenate (open circles), wt-Golgi-enriched
membranes (closed circles), and wt-Golgi subjected to a
20-min stage I incubation (squares) were fractionated by
velocity sedimentation. Fractions were assayed for transport activity
with mut-Golgi in the medial assay. B, wt-Golgi were
fractionated after a 20-min stage I reaction in the presence of
COPI-depleted (open circles) or mock depleted (closed
circles) cytosol, and the activity of the fractions was measured
in the medial assay. C, medial transport activity of
wt-Golgi that were fractionated after a 20-min stage I preincubation
with either ARF-depleted (open circles) cytosol or
ARF-depleted cytosol reconstituted with cytosolic ARFs (closed
circles). D, Western blots of the cytosols used for the
stage I preincubations in B ( -COP) and
C (ARF). The faint bands in the
COPI-depleted lanes that do not increase in intensity with increasing
sample volume correspond to a nonspecific component detected by the
peroxidase-conjugated secondary antibody. Densitometric analysis
indicates that the depleted cytosols contain less than 2% of the
-COP or ARF present in the corresponding mock-depleted
cytosols. Data are representative of two independent experiments.
|
|
When similar samples were fractionated by equilibrium density
centrifugation, nearly identical fractionation profiles were obtained
(data not shown). The Golgi enzyme-containing intermediates produced
both in vivo and in vitro equilibrated at a
density of ~1.06 gm/ml. This is also the approximate density of the
fractions containing the slow sedimenting transport intermediates in
the velocity sedimentation gradients of Figs. 4 and 6. Thus, these sedimentation profiles cannot be strictly interpreted in terms of the
relative size and shape of the functional transport intermediates. Nevertheless, we can conclude that the Golgi enzyme-containing transport intermediates produced in vitro and in
vivo have the same density and that this density is considerably
lower than the density of Golgi cisternae (1.16 g/ml) or COPI-coated
vesicles (1.19 g/ml) (43).
Golgi Enzyme Intermediates Form without COPI Coats--
The
steady-state level of free intermediates produced in the in
vitro system after a 10-min preincubation is highly dependent on
the concentration of cytosol (Fig. 1B, squares).
A straightforward explanation for this cytosol requirement might be
that the steady-state level of free intermediates is dependent on the
amount of Golgi coat proteins available to produce them. COPI is the
dominant coat protein associated with Golgi vesicles, and depletion of COPI from cytosol essentially eliminates the production of coated vesicles on cisternae during an in vitro incubation (26).
Paradoxically, COPI depletion does not inhibit transport in these
in vitro assays (26). It was therefore important to
determine whether COPI depletion would suppress the formation of Golgi
enzyme-containing intermediates during a stage I incubation.
Wt-Golgi membranes were subjected to a 20-min preincubation with either
cytosol depleted of greater than 98% of the endogenous COPI or mock
depleted cytosol (Fig. 6D). The transport mixtures were then
subjected to velocity sedimentation and each fraction tested for
activity in a stage II medial assay. As shown in Fig. 6B,
the profiles of wt-Golgi incubated with COPI-depleted cytosol (open circles) and mock depleted cytosol (closed
circles) were essentially identical, indicating that COPI coats
are not required for the formation of Golgi enzyme-containing transport intermediates.
This finding was verified by performing similar experiments with Golgi
membranes incubated in vitro either with cytosol depleted of
more than 98% of the endogenous ARFs or with ARF-depleted cytosol reconstituted with endogenous ARFs (Fig. 6D). ARF depletion
also reduces COPI vesicle formation on Golgi cisternae to background levels without impairing in vitro transport (26, 27). As
shown in Fig. 6C, the sedimentation profiles of wt-Golgi
after preincubation in the absence (open circles) or
presence (closed circles) of cytosolic ARF were
indistinguishable. We conclude that the formation of functional
transport intermediates containing Golgi enzymes does not require COPI
coats. Moreover, the steady-state levels of free intermediates are
independent of the presence and absence of ARF or COPI. This strongly
suggests that the COPI vesicles that do form during such in
vitro incubations do not make a significant contribution to the
transport detected in the medial assay.
Cargo-containing Intermediates Form without COPI Coats--
The
instability of the VSV G-protein-containing intermediates required that
an alternative approach be used to analyze the involvement of COPI
coats in their formation. We therefore determined whether COPI
depletion could suppress the continuous release of transport
intermediates during multiple rounds of Golgi preincubation, using the
approach illustrated in Fig. 3. In these experiments, the membrane
pellets were not resuspended after each preincubation step, because
previous studies suggested that incubation of Golgi membranes with
COPI-depleted cytosol destabilizes cisternal structure (26). As a
control, the cumulative production of Golgi-enzyme containing
intermediates in the medial assay was also analyzed under the same
conditions (Fig. 7 A). As
expected from the data in Fig. 6, the cumulative release of
intermediates during a preincubation of wt-Golgi with COPI-depleted
cytosol (circles) was nearly identical to that observed with
mock depleted cytosol (squares) in the medial assay.
Significantly, similar results were obtained when the cumulative production of VSV G-protein-containing intermediates from mut-Golgi was
analyzed in the TGN assay (Fig. 7B). The production of
intermediates was the same in the presence (circles) or
absence (squares) of cytosolic COPI for four cycles of
incubation over 20 min. After that time, intermediate production
occurred at a slightly slower rate in the COPI-depleted reaction. This
decline might reasonably be attributed to the greater instability of
the mut-Golgi and their intermediates, which could be enhanced by a
general membrane destabilizing effect of COPI depletion. In all of
these reactions, the continuous harvesting of free intermediates
depleted the transport capacity of the cisternal membranes (Fig. 7,
open symbols). It thus appears that functional intermediates
containing either Golgi enzymes or VSV G-protein are produced by a
COPI-independent mechanism in these in vitro systems.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 7.
Formation of intermediates containing VSV-G
protein is not dependent on COPI coated vesicle formation.
Wt-Golgi for the medial assay (A) or mut-Golgi for the TGN
assay (B) were subjected to repeated cycles of preincubation
and re-isolation without resuspension, as described in Fig.
3A. Both stage I and II contained either COPI-depleted
(squares) or mock-depleted (circles) cytosol (the
same preparations shown in Fig. 6D). The supernatants were
immediately assayed for transport activity with mut-Golgi for the
medial assay (A) or wt-Golgi for the TGN assay
(B). Open symbols denote the activity of the
residual cisternal membranes.
|
|
We conclude that there is no correlation between the concentrations of
ARFs and COPI, the steady-state level of coated vesicles on the Golgi
and the steady-state level of functional transport intermediates
produced by the Golgi during an in vitro incubation. The
de novo production of free intermediates during these
in vitro incubations thus appears to involve a
COPI-independent mechanism.
 |
DISCUSSION |
The mechanism of intra-Golgi transport remains one of the most
hotly debated subjects in intracellular organelle trafficking (for
reviews see Refs. 1, 2-4, 44). Fluorescence imaging of membrane
dynamics in living cells has dramatically expanded our understanding of
transport pathways to and from the Golgi but has not resolved the
details of membrane trafficking within the complex itself. In
vitro reconstitution of intra-Golgi transport has been an
extremely useful tool for identifying transport factors. However, the
fidelity of reconstituted transport to the in vivo transport
process remains a controversial issue, because the unexpected and often
paradoxical behavior of the system has frustrated efforts to provide a
universally acceptable interpretation of the in vitro transport mechanism. We believe that our findings not only resolve some
of these difficulties but reveal novel insights into mechanisms of
intra-Golgi transport that have a greater relevance to the in
vivo process than previously thought.
Preformed Transport Intermediates Verses Steady-state
Production--
Recent studies have suggested that intra-Golgi
transport in modified cell-free systems is mediated by pre-formed
transport intermediates, such as Golgi-derived fusogenic membrane
fragments (29) or Golgi-associated vesicles that had formed in
vivo (42). We believe, however, that the behavior of the cell-free
intra-Golgi transport assays described here can only be fully explained
by the existence of a steady state of Golgi transport intermediate production and consumption during the in vitro incubation.
Dominquez et al. (29) have proposed that in vitro
transport is mediated largely by fusion of Golgi-derived membrane
fragments that are produced during cell homogenization. This conclusion was based on their observation that highly intact rat liver Golgi stacks could not substitute for CHO wt-Golgi in the medial transport assay unless subjected to harsh mechanical disruption. This treatment produced slowly sedimenting cisternal fragments that were both enriched
in Golgi enzymes and highly fusogenic in the assay. Our data indicate
that such fusogenic cisternal fragments make little, if any,
contribution to the transport observed between CHO wt- and mut-Golgi in
the archetypal in vitro system. After isolation, the bulk of
the Golgi enzyme and transport activity of CHO Golgi-enriched membranes
is associated with cisternal membranes and not with slowly sedimenting
membranes (Figs. 4 and 5, closed circles). Functional
transport intermediates are released only after transport incubation
(Fig. 1A), and their continual release does not require additional mechanical disruption of the CHO Golgi (Figs. 3A
and 7). Lastly, fusogenic membrane fragments generated by mechanical disruption would be expected to contain a random sampling of Golgi enzymes and cargo proteins and be able to fuse with other fragments as
well as with cisternal membranes. In contrast, a high degree of
selectivity for both content and fusion partner is exhibited by the
functional transport intermediates found in cell homogenates and
produced by CHO Golgi in vitro (Figs. 2-5). The inability
of highly intact rat liver Golgi to function in the in vitro
transport assay thus appears to be due to a fundamental difference
between rat and CHO Golgi that is unrelated to, but circumvented
by, fragmenting the membranes.
An alternative proposal suggested that transport intermediates formed
in vivo and remaining loosely tethered to isolated Golgi membranes are responsible for transport in the medial assay (42). If
this were true in our intra-Golgi transport assays, then the transport
activity of preincubated wt-Golgi would be expected to decline during a
preincubation, because the pre-existing intermediates would fuse with
wt-Golgi cisternae and be consumed. In contrast, we find only a modest
decline in transport activity even after a 40-min preincubation of
wt-Golgi (Fig. 1A, triangles). Moreover, rather
than observing consumption of intermediates during a preincubation, their level initially rises and then remains constant (Fig.
1A, squares). The persistence of these
intermediates cannot be attributed to a slow release of attached
vesicles from the cisternae, because the transport activity of the
residual cisternal membranes is not depleted during the preincubation
(Fig. 1A, circles). An excess of intermediates
bound to the cisternae can also be ruled out by the fact that transport
capacity of the cisternal membranes can be exhausted by repeatedly
removing the intermediates during a preincubation (Fig. 3,
A-C). We conclude that our data are most consistent with a
rapid establishment of a steady state in transport intermediate
production and consumption during the preincubation and not the release
and fusion of preformed intermediates that would be consumed during the reaction.
It is important to emphasize that there are conditions where
pre-existing transport intermediates might account for all of the
transport signal in these cell-free intra-Golgi transport assays. The
traditional formulation of the medial in vitro assay employs
equal volumes of wt- and mut-Golgi, conditions were the transport
capacity of wt-Golgi is typically well above saturating for the assay
(35). Even though pre-existing intermediates constitute a minor
fraction of wt-Golgi transport capacity, their abundance under these
conditions of excess capacity might be sufficient to drive optimal
transport without de novo generation of intermediates. We
have also observed that repeated freezing and thawing of the membranes
seems to increase the level of free intermediates while impairing the
de novo production of intermediates. It is thus possible
that variations in the quality and concentration of wt-Golgi might
account for some of the contradictory findings and interpretations that
are at the core of the controversy surrounding this cell-free transport system.
Stability of Golgi Membranes during the in Vitro Incubation--
A
final issue is the possibility that Golgi membranes might spontaneously
fragment or disassemble as a consequence of prolonged in
vitro incubation. Several considerations indicate that this is an
unlikely explanation for the production of functional transport intermediates during these in vitro incubations. First, we
and others (45, 46) have demonstrated that Golgi stacks remain intact
and exhibit a normal density of buds after 45-60 min of in
vitro incubation. Consistent with this observation, the transport activity of Golgi membranes sedimented at moderate g force
(1.5 min × 16,000 × g) remains constant for at
least 45 min of incubation (Fig. 1A). Second, although
depletion of COPI or ARF increases the size and number of cisternal
fenestrations, the average number of cisternae per stack and the size
of the cisternae is not significantly altered after 20 min of in
vitro incubation (26, 27). Third, Golgi breakdown, for example, as
occurs upon treatment with mitotic cytosol (47), illimaquinone (48),
okadaic acid (49), or amphipathic peptides (41), results in the
inhibition, not activation, of intra-Golgi transport. A final concern
is that cytosolic proteases might destabilize the membranes during
extended incubations. Fragments formed by such a mechanism are unlikely
to be active, however, because proteolysis of Golgi membranes
eliminates transport competency (35). It thus seems highly improbable
that the production of functional transport intermediates in these
assays is a byproduct of destabilizing conditions arising from the
in vitro incubation per se.
Two Distinct Types of Intra-Golgi Transport Intermediates--
In
the past, the analysis of vesicular intermediates in reconstituted
intra-Golgi transport has been restricted to transport as detected by
complementation of a medial Golgi enzyme defect (19), here termed
medial transport. Although functional VSV G-protein-containing
vesicular intermediates have been demonstrated in this assay (50),
their contribution to in vitro transport appears negligible
in comparison to that of vesicles containing medial Golgi enzyme (30).
Our analysis of three separate reconstitution systems that measure
transport by complementation of medial Golgi, trans Golgi, and
TGN-localized enzymes reveals that the generality of Golgi-enzyme
transport in vesicular intermediates does not extend to the TGN.
As predicted by the cisternal maturation model for transport, the
majority of the in vitro transport in the medial and trans assays can be accounted for by the production of Golgi
enzyme-containing intermediates from wt-Golgi, with only a modest
contribution by VSV-G protein-containing vesicles from mut-Golgi (Figs.
2 and 3). In contrast, essentially no functional carriers were produced by wt-Golgi that could complement the glycosylation defect in the TGN
assay (Fig. 3C). The absence of functional Golgi
enzyme-containing intermediates in the TGN assay appears to be
completely compensated for by the production of functional VSV
G-protein-containing intermediates. For example, in the experiments in
Fig. 3, the cumulative incorporation of sialic acid into VSV G-protein
when mut-Golgi were preincubated was 0.34 pmol and only 0.04 pmol for
preincubation of wt-Golgi. In comparison, the amount of GlcNAc
incorporated into VSV-G protein during preincubation of wt-Golgi was
0.55 pmol, and preincubation of mut-Golgi was 0.11 pmol. These
estimates of transport efficiency are admittedly crude, but are
consistent with expectations if the observed mechanistic differences
are real. Unlike the small VSV G-protein-containing vesicles operating
in the medial assay (50), functional VSV G-protein-containing
intermediates operating the TGN assay are both heterogenous in size and
abundant in cell extracts (Fig. 5). Conversely, functional
TGN-enzyme-containing intermediates are neither produced in
vitro nor detectable in cell extracts. It thus appears that there
is a switch in the mechanism of transport at the boundary between the
trans Golgi and the TGN. The sharpness of this boundary may arise from
the fact that sialylation is restricted almost exclusively to the TGN
in CHO cells (51).
This inability to detect transport intermediates containing TGN enzymes
in intra-Golgi transport was surprising because of the report that
TGN-specific enzymes are transported from the Golgi to the ERGIC
in vitro (42). This discrepancy might be due to a
fundamental difference between in vitro transport within the
Golgi and from the Golgi to the ERGIC. Alternatively, the prolonged
15 °C infection employed by Lin et al. to trap VSV-G protein in the ERGIC might have also resulted in the accumulation of
small amounts of recycling Golgi enzymes in the ERGIC during the
infection. These enzymes could be inactive during the infection, because the in vitro activity of nucleotide-sugar
transporters and Golgi glycosyl transferases is significantly inhibited
at 15 °C.2 A subsequent
in vitro incubation at 37 °C with appropriate nucleotide sugar substrates would, however, unmask their presence. It is thus
possible that the TGN-specific modifications detected by Lin et
al. (42) were not due to in vitro transport of TGN
enzymes to the ERGIC per se but to activation of enzymes
already accumulated in the ERGIC during the 15 °C in vivo
infection. Although this explanation remains to be verified, it leads
us to believe that the difference between our findings and those of Lin
et al. (42) are reconcilable.
The apparent switch in the direction of transport between the trans and
the TGN assays observed here, although unanticipated, may have a
physiological basis. It has long been believed that there is a physical
as well as functional boundary between the cisternal portions of the
Golgi complex and the trans-most tubular reticulum that defines the TGN
(3, 52, 53). The existence of such a boundary was reinforced by the
discovery that TGN marker proteins do not relocate to the ER with other
Golgi marker proteins upon treatment with the fungal metabolite,
brefeldin A (51, 54). Although the precise nature of this boundary
remains elusive, recent tomographic reconstructions of the Golgi
in several cell types have provided structural evidence that sorting of
anterograde cargo proteins into vesicular/tubular carriers may occur
from multiple trans cisternae, as well as the TGN (55, 56). This hypothesis was suggested by the numerous membrane tubules extending from trans cisternae into the region trans of the stack. The VSV G-containing intermediates functioning in the TGN transport assay might
therefore be related to these postulated sorting structures on trans
Golgi cisternae.
Functional Golgi Transport Intermediates Are Not COPI
Vesicles--
It is generally believed that vesicle formation requires
cytoplasmic coat proteins to drive membrane budding and to select vesicle cargo. The analysis of intra-Golgi transport has thus focused
on the role of COPI-coated vesicles, the only known coat protein that
participates in vesicle formation at all levels of the Golgi stack (1,
9, 10, 30). The core of the dispute over the fidelity of reconstitution
in the cell-free transport assays arose from the unexpected finding
that COPI vesicle formation is not required for intra-Golgi transport
in vitro (25-28).
Explanations for this apparent discrepancy have included the
possibility that non-physiological fusion occurs directly between cisternae when COPI vesicle formation is blocked (25), or that the
in vitro system reconstitutes only the fusion of
pre-existing Golgi transport intermediates with cisternae (29, 30). The alternative explanation suggested by our analysis is that the de
novo generation of functional transport intermediates in cell-free Golgi transport occurs by COPI-independent mechanisms (Figs. 6 and 7).
The extents of COPI and ARF depletion attained in this study are
sufficient to nearly or completely eliminate COPI vesicle budding on
Golgi cisternae (26-28). Nevertheless, suppression of COPI vesicle
formation has no effect on the steady-state level of either Golgi
enzyme-containing or VSV G-containing intermediates after 20 min of
preincubation and only slightly impairs production after prolonged and
repeated preincubation (Figs. 6 and 7). Because these functional
transport intermediates appear to be unrelated to COPI-coated vesicles,
it is not necessary to invoke a switch in the mechanism of in
vitro transport to explain the lack of a requirement for COPI or
ARF in these assays.
These data also indicate that the COPI vesicles that do form during a
normal in vitro transport incubation make no detectable contribution to in vitro transport. Although COPI vesicles
formed in vitro might simply be non-functional, it is just
as likely that the acceptor compartment for these vesicles lies outside the Golgi stack, and thus the detection capabilities of these assays.
The absence of a requirement for cytosolic ARF in these intra-Golgi
transport assays further indicates that other ARF-dependent coat proteins, such as AP1 (57) or the trans Golgi/TGN vesicle coat
proteins called GGAs (Golgi-localizing, gamma-adaptin ear homology
domain, ARF-binding proteins) (58, 59) are not involved. It is
important to note that, even though coated vesicles are abundant on
Golgi cisternae after an in vitro incubation, a low but
constant density of uncoated vesicles, buds, and tubules are present,
even when COPI vesicle formation is blocked (27). It is thus possible
that these uncoated elements correspond to the functional transport
intermediates detected in these in vitro assays.
Alternatives to COPI-dependent Transport--
There is
now an in vivo precedent for COPI-independent transport of
Golgi enzymes. The constitutive recycling of Golgi enzymes to the ER
involves a Rab6-dependent pathway that is distinct from the
COPI-dependent pathway to the ER (31, 32). The Rab6
transport intermediates appear as dynamic globular and tubular carriers that not only translocate toward the ER but emerge from and re-enter or
retract into the Golgi (32). This behavior, which might be expected for
intra-Golgi transport intermediates, has also been observed with Golgi
enzyme-green fluorescence protein chimeras in vivo (18). It
is thus possible the same Rab6-dependent mechanism, or a
similar mechanism regulated by related Golgi Rabs, such as Rab6A' (60)
or Rab33b (61), is responsible for the trafficking of Golgi enzymes
within the stack itself. The fact that Rab6 antibodies and Rab6 mutants
defective in GTP-binding inhibit the medial cell-free transport assay
(62) makes this an attractive possibility.
The morphogenesis of post-Golgi tubular carriers is not well understood
and there are as yet no other in vivo precedents for coat
protein-independent sorting of anterograde cargo. It has, however, been
demonstrated in vitro that sorting of cargo into tubules of
the transitional ER can occur in the absence of ER coat proteins (63).
If the segregation of secretory cargo and membrane deformation does not
necessarily require coat proteins, it is reasonable to expect that
other physiologically relevant coat protein-independent mechanisms of
sorting and transport remain to be discovered.
Obviously, until such time when both types of transport intermediates
generated by the Golgi in vitro can be isolated and characterized, their origin and relationship to physiological carriers
remains necessarily speculative. Nevertheless, we believe our analysis
indicates a need to look beyond the constraints imposed by ARF and coat
protein-dependent transport mechanisms (64). The
morphogenesis and dynamics of the pleiomorphic carriers that figure so
prominently in living cells (65, 66) clearly warrant more consideration
in conceptualizing mechanisms for intra-Golgi transport.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Steve Scholnick and Maurine
Linder for critical comments on the manuscript, Dr. Monty Krieger for
suggestions, and Dr. Joachim Ostermann for CM1A10 antibodies.
 |
FOOTNOTES |
*
This work was supported by Grant GM54428 from the National
Institutes of Health (to P. J. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Department of Cell Biology and Neuroscience,
University of California, Riverside, CA 92521.
§
To whom correspondence should be addressed: Dept. of Biochemistry
and Molecular Biology, St. Louis University School of Medicine, 1402 South Grand Blvd., M173, St. Louis, MO 63104. Tel.: 314-577-8179; Fax:
314-577-8156; E-mail: weidmanp@slu.edu.
Published, JBC Papers in Press, October 18, 2002, DOI 10.1074/jbc.M209341200
2
P. Weidman, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
ER, endoplasmic
reticulum;
ARF, ADP-ribosylation factor;
CHO, Chinese hamster ovary;
GlcNAc, N-acetylglucosamine;
GlcNAcT, N-acetylglucosaminyl transferase;
mut-Golgi, Golgi-enriched
fractions from glycosylation defective cells;
SA, sialic acid;
TGN, trans Golgi network;
wt-Golgi, Golgi-enriched fractions from wild type
cells;
VSV G-protein, vesicular stomatitis virus glycoprotein;
ERGIC, ER-Golgi intermediate compartment;
COPI, coatomer (coat protein complex I).
 |
REFERENCES |
| 1.
|
Allan, B. R.,
and Balch, W. E.
(1999)
Science
285,
63-66[Abstract/Free Full Text]
|
| 2.
|
Glick, B. S.,
and Malhotra, V.
(1998)
Cell
95,
883-889[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Mellman, I.,
and Simons, K.
(1992)
Cell
68,
829-840[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Pelham, H. R. B.,
and Rothman, J. E.
(2000)
Cell
102,
713-719[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Cosson, P.,
and Letourneur, F.
(1997)
Curr. Opin. Cell Biol.
9,
484-487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Letourneur, F.,
Gaynor, E. C.,
Hennecke, S.,
Demolliere, C.,
Duden, R.,
Emr, S. D.,
Riezman, H.,
and Cosson, P.
(1994)
Cell
79,
1199-1207[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Rothman, J. E.
(1994)
Nature
372,
55-63[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Rothman, J. E.,
and Wieland, F. T.
(1996)
Science
272,
227-234[Abstract]
|
| 9.
|
Orci, L.,
Amherdt, M.,
Ravazzola, M.,
Perrelet, A.,
and Rothman, J. E.
(2000)
J. Cell Biol.
150,
1263-1270[Abstract/Free Full Text]
|
| 10.
|
Orci, L.,
Stamnes, M.,
Ravazzola, M.,
Amherdt, M.,
Perrelet, A.,
Söllner, T. H.,
and Rothman, J. E.
(1997)
Cell
90,
335-349[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Volchuk, A.,
Amherdt, M.,
Ravazzola, M.,
Brugger, B.,
Rivera, V. M.,
Clackson, T.,
Perrelet, A.,
Sollner, T. H.,
Rothman, J. E.,
and Orci, L.
(2000)
Cell
102,
335-348[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Martinez-Menarguez, J. A.,
Prekeris, R.,
Oorschot, V. M.,
Scheller, R.,
Slot, J. W.,
Geuze, H. J.,
and Klumperman, J.
(2001)
J. Cell Biol.
155,
1213-1224[Abstract/Free Full Text]
|
| 13.
|
Bonfanti, L.,
Mironov, J. A. A.,
Martinez-Menarguez, J. A.,
Martella, O.,
Fusella, A.,
Baldassarre, M.,
Buccione, R.,
Geuze, H. J.,
Mironov, A. A.,
and Luini, A.
(1998)
Cell
95,
993-1003[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Mironov, A. A.,
Beznoussenko, G. V.,
Nicoziani, P.,
Martella, O.,
Trucco, A.,
Kweon, H. S., Di,
Giandomenico, D.,
Polishchuk, R. S.,
Fusella, A.,
Lupetti, P.,
Berger, E. G.,
Geerts, W. J.,
Koster, A. J.,
Burger, K. N.,
and Luini, A.
(2001)
J. Cell Biol.
155,
1225-1238[Abstract/Free Full Text]
|
| 15.
|
Lanoix, J.,
Ouwendijk, J.,
Lin, C.-C.,
Stark, A.,
Love, H. D.,
Ostermann, J.,
and Nilsson, T.
(1999)
EMBO J.
18,
4935-4948[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Hirschberg, K.,
Miller, C. M.,
Ellenberg, J.,
Presley, J. F.,
Siggia, E. D.,
Phair, R. D.,
and Lippincott-Schwartz, J.
(1998)
J. Cell Biol.
143,
1485-1503[Abstract/Free Full Text]
|
| 17.
|
Presley, J. F.,
Cole, N. B.,
Schroer, T. A.,
Hirschberg, K.,
Zaal, K. J. M.,
and Lippincott-Schwartz, J.
(1997)
Nature
389,
81-85[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Sciaky, N.,
Presley, J.,
Smith, C.,
Zaal, K. J. M.,
Cole, N.,
Moreira, J. E.,
Terasaki, M.,
Siggia, E.,
and Lippincott-Schwartz, J.
(1997)
J. Cell Biol.
139,
1137-1155[Abstract/Free Full Text]
|
| 19.
|
Balch, W. E.,
Dunphy, W. G.,
Braell, W. A.,
and Rothman, J. E.
(1984)
Cell
39,
405-416[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Serafini, T.,
Orci, L.,
Amherdt, M.,
Brunner, M.,
Kahn, R. A.,
and Rothman, J. E.
(1991)
Cell
67,
239-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Waters, M. G.,
Serafini, T.,
and Rothman, J. E.
(1991)
Nature
349,
248-251[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Duden, R.,
Griffiths, G.,
Frank, R.,
Argos, P.,
and Kries, T. E.
(1991)
Cell
64,
649-665[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Orci, L.,
Glick, B. S.,
and Rothman, J. E.
(1986)
Cell
46,
171-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Serafini, T.,
Stenbeck, G.,
Brecht, A.,
Lottspeich, F.,
Orci, L.,
Rothman, J. E.,
and Wieland, F. T.
(1991)
Nature
349,
215-220[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Elazar, Z.,
Orci, L.,
Ostermann, J.,
Amherdt, M.,
Tanigawa, G.,
and Rothman, J. E.
(1994)
J. Cell Biol.
124,
415-424[Abstract/Free Full Text]
|
| 26.
|
Happe, S.,
Cairns, M.,
Roth, R.,
Heuser, J.,
and Weidman, P.
(2000)
Traffic
1,
342-353[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Happe, S.,
and Weidman, P.
(1998)
J. Cell Biol.
140,
511-523[Abstract/Free Full Text]
|
| 28.
|
Taylor, T. C.,
Kanstein, M.,
Weidman, P.,
and Melançon, P.
(1994)
Mol. Biol. Cell
5,
237-252[Abstract]
|
| 29.
|
Dominguez, M.,
Fazel, A.,
Dahan, S.,
Lovell, J.,
Hermo, L.,
Claude, A.,
Melançon, P.,
and Bergeron, J. J. M.
(1999)
J. Cell Biol.
145,
673-688[Abstract/Free Full Text]
|
| 30.
|
Love, H. D.,
Lin, C.-C.,
Short, C. S.,
and Ostermann, J.
(1998)
J. Cell Biol.
140,
541-551[Abstract/Free Full Text]
|
| 31.
|
Girod, A.,
Storrie, B.,
Simpson, J. C.,
Johannes, L.,
Goud, B.,
Roberts, L. M.,
Lord, J. M.,
Nilsson, T.,
and Pepperkok, R.
(1999)
Nature Cell Biol.
1,
423-430[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
White, J.,
Johannes, L.,
Mallard, F.,
Girod, A.,
Grill, S.,
Reinsch, S.,
Keller, P.,
Tzschaschel, B.,
Echard, A.,
Goud, B.,
and Stelzer, E. H.
(1999)
J. Cell Biol.
147,
743-760[Abstract/Free Full Text]
|
| 33.
|
Block, M. R.,
Glick, B. S.,
Wilcox, C. A.,
Wieland, F. T.,
and Rothman, J. E.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
7852-7856[Abstract/Free Full Text]
|
| 34.
|
Clary, D. O.,
and Rothman, J. E.
(1990)
J. Biol. Chem.
265,
10109-10117[Abstract/Free Full Text]
|
| 35.
|
Balch, W. E.,
and Rothman, J. E.
(1985)
Arch. Biochem. Biophys.
240,
413-425[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Rothman, J. E.
(1987)
J. Biol. Chem.
262,
12502-12510[Abstract/Free Full Text]
|
| 37.
|
Stanley, P.,
and Siminovitch, L.
(1977)
Somatic Cell Genet.
3,
391-405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Deutscher, S. L.,
and Hirschberg, C. B.
(1986)
J. Biol. Chem.
261,
96-100[Abstract/Free Full Text]
|
| 39.
|
Deutscher, S. L.,
Nuwayhid, N.,
Stanley, P.,
Briles, E. B.,
and Hirschberg, C. B.
(1984)
Cell
39,
295-299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Briles, E. B., Li, E.,
and Kornfeld, S.
(1977)
J. Biol. Chem.
252,
1107-1116[Abstract/Free Full Text]
|
| 41.
|
Weidman, P. J.,
and Winter, W. M.
(1994)
J. Cell Biol.
127,
1815-1827[Abstract/Free Full Text]
|
| 42.
|
Lin, C.-C.,
Love, H. D.,
Gushue, J. N.,
Bergeron, J. J. M.,
and Ostermann, J.
(1999)
J. Cell Biol.
147,
1457-1472[Abstract/Free Full Text]
|
| 43.
|
Malhotra, V.,
Serafini, T.,
Orci, L.,
Shepard, J. C.,
and Rothman, J. E.
(1989)
Cell
58,
329-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Barr, F. A.
(2002)
Trends Cell Biol.
12,
101-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Braell, W. A.,
Balch, W. E.,
Dobbertin, D. C.,
and Rothman, J. E.
(1984)
Cell
39,
511-524[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Weidman, P.,
Roth, R.,
and Heuser, J.
(1993)
Cell
75,
123-133[Medline]
[Order article via Infotrieve]
|
| 47.
|
Stuart, R. A.,
Mackay, D.,
Adamczewski, J.,
and Warren, G.
(1993)
J. Biol. Chem.
268,
4050-4054[Abstract/Free Full Text]
|
| 48.
|
Takizawa, P. A.,
Yucel, J. K.,
Veit, B.,
Faulkner, D. J.,
Deerinck, T.,
Soto, G.,
Ellisman, M.,
and Malhotra, V.
(1993)
Cell
73,
1079-1090[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Lucocq, J.,
Warren, G.,
and Pryde, J.
(1991)
J. Cell Sci.
100,
753-759[Abstract/Free Full Text]
|
| 50.
|
Ostermann, J.,
Orci, L.,
Tani, K.,
Amherdt, M.,
Ravazzola, M.,
Elazar, Z.,
and Rothman, J. E.
(1993)
Cell
75,
1015-1025[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Chege, N. W.,
and Pfeffer, S. R.
(1990)
J. Cell Biol.
111,
893-899[Abstract/Free Full Text]
|
| 52.
|
Griffiths, G.
(2000)
Traffic
1,
738-745[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Griffiths, G.,
and Simons, K.
(1986)
Science
234,
438-443[Abstract/Free Full Text]
|
| 54.
|
Wood, S. A.,
Park, J. E.,
and Brown, W. J.
(1991)
Cell
67,
591-600[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Marsh, B. J.,
Mastronarde, D. N.,
Buttle, K. F.,
Howell, K. E.,
and McIntosh, J. R.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
2399-2406[Abstract/Free Full Text]
|
| 56.
|
Marsh, B. J.,
Mastronarde, D. N.,
McIntosh, J. R.,
and Howell, K. E.
(2001)
Biochem. Soc. Trans.
29,
461-467[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Stamnes, M. A.,
and Rothman, J. E.
(1993)
Cell
73,
999-1005[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Dell'Angelica, E. C.,
Puertollano, R.,
Mullins, C.,
Aguilar, R. C.,
Vargas, J. D.,
Hartnell, L. M.,
and Bonifacino, J. S.
(2000)
J. Cell Biol.
149,
81-94[Abstract/Free Full Text]
|
| 59.
|
Hirst, J.,
Lui, W. W.,
Bright, N. A.,
Totty, N.,
Seaman, M. N.,
and Robinson, M. S.
(2000)
J. Cell Biol.
149,
67-80[Abstract/Free Full Text]
|
| 60.
|
Echard, A.,
Opdam, F. J. M.,
de Leeuw, H.,
Jollivet, F.,
Savelkoul, P.,
Hendriks, W.,
Voorberg, A.,
Goud, B.,
and Fransen, J. A. M.
(2000)
Mol. Biol. Cell
11,
3819-3833[Abstract/Free Full Text]
|
| 61.
|
Valsdottir, R.,
Hashimoto, H.,
Ashman, K.,
Koda, T.,
Storrie, B.,
and Nilsson, T.
(2001)
FEBS Lett.
508,
201-209[CrossRef][Medline]
[Order article via Infotrieve]
|
| 62.
|
Mayer, T.,
Touchot, N.,
and Elazar, Z.
(1996)
J. Biol. Chem.
271,
16097-16103[Abstract/Free Full Text]
|
| 63.
|
Aridor, M.,
Fish, K. N.,
Bannykh, S. I.,
Weissman, J.,
Roberts, T. H.,
Lippincott-Schwartz, J.,
and Balch, W. E.
(2001)
J. Cell Biol.
152,
213-229[Abstract/Free Full Text]
|
| 64.
|
Stephens, D. J.,
and Pepperkok, R.
(2001)
J. Cell Sci.
114,
1053-1059[Abstract]
|
| 65.
|
Lippincott-Schwartz, J.,
Roberts, T. H.,
and Hirschberg, K.
(2000)
Annu. Rev. Cell Dev. Biol.
16,
557-589[CrossRef][Medline]
[Order article via Infotrieve]
|
| 66.
|
Polishchuk, R. S.,
Polishchuk, E. V.,
Marra, P.,
Alberti, S.,
Buccione, R.,
Luini, A.,
and Mironov, A. A.
(2000)
J. Cell Biol.
148,
45-58[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H.-S. Kweon, G. V. Beznoussenko, M. Micaroni, R. S. Polishchuk, A. Trucco, O. Martella, D. Di Giandomenico, P. Marra, A. Fusella, A. Di Pentima, et al.
Golgi Enzymes Are Enriched in Perforated Zones of Golgi Cisternae but Are Depleted in COPI Vesicles
Mol. Biol. Cell,
October 1, 2004;
15(10):
4710 - 4724.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|